Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis

被引:42
作者
Andrade, SE
Graham, DJ
Staffa, JA
Schech, SD
Shatin, D
La Grenade, L
Goodman, MJ
Platt, R
Gurwitz, JH
Chan, KA
机构
[1] Univ Massachusetts, Sch Med, Meyers Primary Care Inst, Fallon Fdn, Worcester, MA 01605 USA
[2] Ctr Drug Evaluat & Res, Off Drug Safety, Rockville, MD 20857 USA
[3] Ctr Hlth Care Policy & Evaluat, Eden Prairie, MN 55344 USA
[4] HealthPartners Res Fdn, Minneapolis, MN 55425 USA
[5] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02115 USA
[7] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
关键词
positive predictive value; myopathy; rhabdomyolysis; automated databases; statins; fibrates;
D O I
10.1016/j.jclinepi.2004.10.004
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: We evaluated the positive predictive values (PPVs) of specific criteria based upon International Classification of Diseases, 9th revision (ICD-9-CM) codes documented in health plan administrative databases for identification of cases of serious myopathy and rhabdomyolysis. Study Design and Setting: We conducted a retrospective study among patients enrolled in I I geographically dispersed managed care organizations. Cohorts of new users of specific statins and fibrates were identified by selecting patients with an initial dispensing of the drug during the period 1 January 1998 to 30 June 2001. Potential cases of serious myopathy or rhabdomyolysis were identified using specific criteria based upon ICD-9-CM codes suggesting a muscle disorder or acute renal failure. Results: A total of 194 hospitalizations meeting the criteria for chart review selection were identified among 206,732 new users of statins and 15,485 new users of fibrates. Overall, 31 cases of serious, clinically important myopathy or rhabdomyolysis (18%) were confirmed through chart review. Of these, 26 (84%) had a claim including codes for myoglobinuria (ICD-9-CM 791.3) or other disorders of muscle, ligament, and fascia (ICD-9-CM 728.89). A PPV of 74% (26 of 35 patients meeting criteria) was found for a composite definition that included (1) a primary or secondary discharge code for myoglobinuria, (2) a primary code for "other disorders of muscle," or (3) a secondary code for "other disorders of muscle" accompanied by a claim for a CK test within 7 days of hospitalization or a discharge code for acute renal failure. Conclusion: For rare adverse events such as serious myopathy or rhabdomyolysis, large population-based databases that include diagnosis and laboratory test claims data can facilitate epidemiologic research. (C) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:171 / 174
页数:4
相关论文
共 7 条
  • [1] Risk for myopathy with statin therapy in high-risk patients
    Ballantyne, CM
    Corsini, A
    Davidson, MH
    Holdaas, H
    Jacobson, TA
    Leitersdorf, E
    März, W
    Reckless, JPD
    Stein, EA
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (05) : 553 - 564
  • [2] Etiology and frequency of rhabdomyolysis
    Black, C
    Jick, H
    [J]. PHARMACOTHERAPY, 2002, 22 (12): : 1524 - 1526
  • [3] Lipid-lowering drugs and risk of myopathy:: A population based follow-up study
    Gaist, D
    Rodríguez, LAG
    Huerta, C
    Hallas, J
    Sindrup, SH
    [J]. EPIDEMIOLOGY, 2001, 12 (05) : 565 - 569
  • [4] Cerivastatin and reports of fatal rhabdomyolysis.
    Staffa, JA
    Chang, J
    Green, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) : 539 - 540
  • [5] Statin-associated myopathy
    Thompson, PD
    Clarkson, P
    Karas, RH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (13): : 1681 - 1690
  • [6] HMG-CoA reductase inhibitors and myotoxicity
    Ucar, M
    Mjörndal, T
    Dahlqvist, R
    [J]. DRUG SAFETY, 2000, 22 (06) : 441 - 457
  • [7] WORMANN RL, 2002, CURR OPIN RHEUMATOL, V14, P643